Document text
Principal Investigator: Donald Lo
Organization: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Fiscal Year: 2021
Award: $3,643,319
Funding agency: National Center for Advancing Translational Sciences
We have worked in collaboration with experts in and outside of NIH on the development of 8 assays for use in repurposing screens of approved drug collections to identify compounds active against SARS-CoV-2. The compounds identified from such screens have potential for clinical trials as single agents or in drug combinations to treat COVID-19 patients.
1. A SARS-CoV-2 pseudotyped particle (PP) entry assay in collaboration with Gary Whittaker (Cornell University). The PPs were generated with three plasmid transfection system containing MLV gag-pol, CoV spike, and luciferase reporter gene w/ viral packaging signal. In the assay process, the PPs deliver luciferase reporter RNA to host cells via spike-mediated cell entry. This assay has been used for screen the inhibitors of SARS-CoV-2 entry as well as the mechanistic study of other compounds identified from other assays. Recently, we have applied this assay to several variants of spike mutations to monitor the potential changes of sensitivities to current therapeutics.
2. SARS pseudotyped particle (PP) entry assay and MERS entry assays in collaboration with Gary Whittaker (Cornell University). Both assays have been optimized for 1536-well screens and used for drug repurposing screens of approved drug collection. The identified hits were further evaluated in a cytopathic effect assay with live SARS-CoV-2 infection (Southern Research Institute) to identify anti-SARS-CoV2 compounds that have broad activity against coronaviruses.
3. A SARS-CoV-2 cytopathic effect assay in Vero 6 cells in collaboration with the Southern Research Institute (SRI). Several small collections of approximately 10,000 approved and investigational drugs, preclinical drug candidates, and bioactive compounds were screened using assay ready plates, prepared by NCATS, in the BSL-3 lab at SRI. This assay has also been used to evaluate anti-SARS-CoV-2 compounds identified from NCATSs BSL-2 assays.
4. A SARS-CoV-2 3CL protease (also named main protease) assay. This viral protease plays a critical role in SARS-CoV-2 viral replication. We have developed and optimized this enzyme assay and screened a collection of approximately 10,000 compounds. Currently, a virtual modeling screen of the entire NCATS compound collection is in progress using the data from this focused library screen as a training set. The lead compounds will be used for chemistry optimization for further drug development.
5. A SARS-CoV-2 RNA dependent RNA polymerase (RdRP) assay. This viral RNA polymerase is critical to SARS-CoV-2 viral replication in host cells. Remdesivir, an RdRP inhibitor originally developed for Ebola virus and other viruses, has been authorized by the FDA for emergency use in hospitalized COVID-19 patients. The efficacy and potency of this drug are limited for SARS-CoV-2, as it was not originally developed for this virus. Remdesivir is currently only administered by intravenous infusion that precludes it from outpatient treatment. We are developing a SARS-CoV-2 RdRP enzyme assay and a cell-based RdRP assay to support repurposing screens for new drug development.
6. A SARS-CoV-2 replicon assay for use BSL-2 laboratories. Research involving live SARS-CoV-2 virus requires BSL-3 facility, which greatly limits throughput. We are collaborating with three laboratories to develop a replicon type assay for SARS-CoV-2, similar to our previous work on HCV. This replicon assay will have a SARS-CoV-2 genomic fragment encompassing viral replication machinery, without the viral envelop proteins, and will include a mini-genome reporter gene (luciferase). We will use this assay to screen NCATS compound collections for drug discovery and development.
7. An AlphaLISA assay to detect the SARS-CoV-2 Nucleocapsid (N) protein. Currently, the cytopathic effect (CPE) assay of SARS-CoV-2 allows for the greatest throughput in BSL-3 laboratories, but uses a surrogate readout for host cell infection (cell death). The AlphaLISA N protein assay would allow BSL-3 labs to directly measure viral antigen production upon SARS-CoV-2 infection in host cells. This assay is homogenous and amenable to HTS. It was developed to help increase the throughput of BSL3 labs.
8. A TR-FRET (HTRF) assay to detect the SARS-CoV-2 Nucleocapsid (N) protein. This assay is similar to the AlphaLISA N protein assay, but uses a different readout. This assay could be used as an alternative assay for HTS, or as an orthogonal assay to confirm the hits identified from the above AlphaLISA assay.
We also have begun projects to rapidly progress candidates into clinical trials for SARS-CoV-2. In one project, our collaborators recently completed phase I trials of a protein natural product for as a microbicide against HIV. Its mechanism of action, selectively binding to high-mannose oligosaccharides on viral envelope glycoproteins, is relevant to diverse pathogens, including HIV, Influenza, Ebolavirus, and SARS-CoV. The candidate has shown in vitro and in vivo activity against several coronaviruses, including SARS-CoV and MERS-CoV. Because it binds the spike glycoprotein on SARS-CoV, it is likely to have activity against all coronavirus strains, not only the SARS-CoV-2 driving the current COVID-19 pandemic.
The second project involves developing a metabolite of remdesivir, a nucleoside analog antiviral, as an orally available therapy. Currently, remdesivir is used to treat moderate-to-advanced SARS-CoV-2 infection, but it requires intravenous administration in a hospital setting. Current clinical and preclinical data support the hypothesis that an orally active nucleoside analog may be especially useful for treating early-stage disease and would be more suitable for global distribution than the more medically complex intravenous approach.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Advanced Development><Ambulatory Care><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Automobile Driving><BSL-3 facility><BSL3 facility><Binding><Bioassay><Bioavailability><Biologic Assays><Biologic Availability><Biological><Biological Assay><Biological Availability><COVID associated pneumonia><COVID crisis><COVID epidemic><COVID induced pneumonia><COVID infected patient><COVID pandemic><COVID patient><COVID pneumonia><COVID positive patient><COVID related pneumonia><COVID-19><COVID-19 assay><COVID-19 associated pneumonia><COVID-19 crisis><COVID-19 detection><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 induced pneumonia><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 pneumonia><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 related pneumonia><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID19><COVID19 detection><COVID19 assay><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 therapy><COVID19 treatment><COVID19 virus><CV-19><CV19><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Chemistry><Clinical><Clinical Evaluation><Clinical Testing><Clinical Trials><CoV-2><CoV2><Collaborations><Collection><Communities><Complex><Coronaviridae><Coronavirus><D-Mannose><DNA-Dependent RNA Polymerases><DNA-Directed RNA Polymerase><Data><Development><Disease><Disorder><Drug Combinations><Drug usage><Drugs><EBOV><EC 2.7.7.48><Ebola virus><Ebola-like Viruses><Emergencies><Emergency Situation><Enzyme Gene><Enzymes><Esteroproteases><FRET><Fluorescence Resonance Energy Transfer><Förster Resonance Energy Transfer><GS-5734><Genetic Alteration><Genetic Change><Genetic defect><Genome><Genomics><Glycoproteins><Grippe><HCV><HIV><Hepatitis C virus><Hospitals><Human><Human Immunodeficiency Viruses><IV Infusion><In Vitro><Infection><Influenza><Intracellular Communication and Signaling><Intravenous><Intravenous infusion procedures><Investigational Drugs><Investigational New Drug Application><Investigational New Drugs><Investigators><Joints><LAV-HTLV-III><Laboratories><Lead><Libraries><Luciferase Immunologic><Luciferases><Lymphadenopathy-Associated Virus><MERS><MERS corona virus><MERS coronavirus><MERS coronavirus disease><MERS virus><MERS-CoV><MERS-CoV disease><Mannopyranose><Mannopyranoside><Mannose><Measures><Mediating><Medical><Medication><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome coronavirus disease><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome-CoV><Modern Man><Molecular Interaction><Monitor><Mutation><NIH><Names><National Institutes of Health><Natural Products><Non-Polyadenylated RNA><Nucleocapsid Proteins><Oligosaccharides><Oral><Outpatient Care><PK/PD><Pb element><Peptidases><Peptide Hydrolases><Pharmaceutic Preparations><Pharmaceutical Preparations><Physiologic Availability><Plasmids><Play><Position><Positioning Attribute><Process><Production><Protease Gene><Proteases><Proteinases><Proteins><Proteolytic Enzymes><Public Health><RNA><RNA Gene Products><RNA Polymerase Inhibitor><RNA Polymerases><RNA Replicase><RNA-Dependent RNA Polymerase><RNA-Directed RNA Polymerase><Replication Unit><Replicon><Reporter><Reporter Genes><Research><Research Activity><Research Institute><Research Personnel><Research Support><Researchers><Ribonucleic Acid><Role><SARS><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS coronavirus disease><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV disease><SARS-CoV-2><SARS-CoV-2 assay><SARS-CoV-2 associated pneumonia><SARS-CoV-2 detection><SARS-CoV-2 entry inhibitor><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 induced pneumonia><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 pneumonia><SARS-CoV-2 positive patient><SARS-CoV-2 related pneumonia><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientist><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 entry inhibitor><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Signal Transduction><Signal Transduction Systems><Signaling><Societies><System><Testing><Therapeutic><Therapeutic Intervention><Toxicology><Training><Transfection><Translational Research><Translational Science><United States National Institutes of Health><Universities><Vaccines><Variant><Variation><Veklury><Viral><Viral Antigens><Viral Packaging><Virus><Virus Packagings><Virus Replication><Virus-HIV><Work><Wuhan coronavirus><anti-viral agents><anti-viral drugs><anti-viral nucleoside analog><anti-virals><antiviral nucleoside analog><atypical pneumonia><base><beta CoV><beta coronavirus><betaCoV><betacoronavirus><biological signal transduction><biosafety level 3 facility><block SARS-CoV-2 entry><block severe acute respiratory syndrome coronavirus 2 entry><clinical candidate><clinical development><clinical efficacy><clinical investigation><clinical test><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 assay><coronavirus disease 2019 associated pneumonia><coronavirus disease 2019 crisis><coronavirus disease 2019 detection><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 induced pneumonia><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 pneumonia><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 related pneumonia><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease associated pneumonia><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease induced pneumonia><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease pneumonia><coronavirus disease positive patient><coronavirus disease related pneumonia><coronavirus patient><detect COVID-19><detect COVID19><detect SARS-CoV-2><detect severe acute respiratory syndrome coronavirus 2><developmental><driving><drug candidate><drug development><drug discovery><drug repurposing><drug use><drug/agent><ebolavirus><genome mutation><hCoV19><heavy metal Pb><heavy metal lead><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2 entry><inhibit severe acute respiratory syndrome coronavirus 2 entry><intervention therapy><intravenous administration><intravenous infusion><microbicidal><microbicide><model development><nCoV2><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel therapeutics><novel therapy><nucleoside analog><operation><outpatient treatment><pandemic><pandemic disease><particle><pathogen><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pharmacokinetics and pharmacodynamics><phase 1 trial><phase I trial><pneumonia due to COVID><pneumonia due to COVID-19><pneumonia due to SARS-CoV-2><pneumonia due to coronavirus disease><pneumonia due to coronavirus disease 2019><pneumonia due to severe acute respiratory syndrome coronavirus 2><pneumonia in COVID><pneumonia in COVID-19><pneumonia in SARS-CoV-2><pneumonia in coronavirus disease><pneumonia in coronavirus disease 2019><pneumonia in severe acute respiratory syndrome coronavirus 2><pre-clinical><preclinical><remdesivir><repurposing agent><repurposing medication><research clinical testing><severe acute respiratory syndrome coronavirus 2 assay><severe acute respiratory syndrome coronavirus 2 associated pneumonia><severe acute respiratory syndrome coronavirus 2 detection><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 induced pneumonia><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 pneumonia><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 related pneumonia><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome-CoV><small molecule><social role><therapeutic agent development><therapeutic candidate><therapeutic development><translation research><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><viral RNA><viral multiplication><viral replication><virtual model><virus RNA><virus antigen><virus multiplication><β CoV><β coronavirus><βCoV>